{"entity":{"id":"hcw11-018b","kind":"drug","name":"HCW11-018b","aka":[],"tldr":"HCW11-018b is an experimental injection under the skin designed to direct the body's T cells against solid tumours. HCW Biologics plans to ask the US regulator in 2027 for permission to begin its first trial in people.","summary":"HCW11-018b is an investigational tetravalent T-cell engager from HCW Biologics, administered by subcutaneous injection and developed to treat solid tumours. HCW Biologics' 2026 S-1 states that after a Type B pre-IND meeting with the FDA in July 2026 the company received direction on preparing to start a Phase 1 trial in solid tumours, with the IND planned for the first half of 2027. The filing does not name the tumour antigen or the tumour types.","status":"preclinical","asOf":"2026-11-04","links":[{"label":"SEC EDGAR: HCW Biologics S-1, October 2026","url":"https://www.sec.gov/Archives/edgar/data/1828673/000149315226045532/forms-1.htm"}],"tags":["pipeline"],"related":[],"cancers":[],"sections":[],"technologies":["t-cell-engager"],"targets":[],"drugs":[],"companies":["hcw-biologics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo startup monitors","editedOn":"2026-11-04"},"code":"HCW11-018b","modality":"Tetravalent T-cell engager (fusion protein, subcutaneous)","mechanism":"A tetravalent T-cell engager given by subcutaneous injection, as HCW Biologics' filing describes it: a multi-armed fusion molecule built to bring T cells into contact with tumour cells. The filing does not name the tumour antigen.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/hcw11-018b/","neighbours":{"technology":[{"id":"t-cell-engager","kind":"technology","name":"T-cell engagers (bispecific)","route":"/technologies/t-cell-engager/"}],"company":[{"id":"hcw-biologics","kind":"company","name":"HCW Biologics","route":"/companies/hcw-biologics/"}]}}